Related Experiment Videos
[Therapeutic effect of ceftizoxime on infection in patients with lung cancer]
Abstract:
Ceftizoxime (CZX) was given in daily doses of 4 approximately 6 g by intravenous drip infusion to 30 patients with infection accompanying lung cancer to investigate the usefulness of the drug for infectious disease: The rate of effectiveness (marked and moderate) was 73.3% (22/30 patients). Of the 30 patients, 2 had drug fever; 1, arthralgia; and 1, eosinophilia. These side effects improved after the drug was withdrawn. CZX is a very useful antibiotic with high effectiveness and safety in immunocompromised patients with infection accompanying advanced lung cancer.
Insights
Ceftizoxime (CZX) demonstrated 73.3% effectiveness in treating infections in lung cancer patients. This antibiotic showed high safety and usefulness in immunocompromised individuals.
Area of Science:
- Infectious Diseases
- Oncology
- Pharmacology
Context:
- Patients with advanced lung cancer often experience infections, compromising their immune status.
- Assessing the efficacy of antibiotics in immunocompromised patient populations is crucial for effective treatment strategies.
Purpose:
- To evaluate the clinical usefulness and safety of Ceftizoxime (CZX) in treating infections in patients with lung cancer.
- To determine the effectiveness rate and identify potential side effects of CZX in this specific patient group.
Summary:
- Ceftizoxime (CZX) was administered intravenously at daily doses of 4-6g to 30 patients with infections accompanying lung cancer.
- An overall effectiveness rate of 73.3% (22/30) was observed, with marked or moderate responses.
- Reported side effects included drug fever, arthralgia, and eosinophilia, all of which resolved upon drug discontinuation.
Impact:
- Ceftizoxime (CZX) presents a highly effective and safe therapeutic option for managing infections in immunocompromised patients with advanced lung cancer.
- The findings support the use of CZX as a valuable antibiotic in oncological patient care, improving treatment outcomes for associated infections.